Side-by-Side Comparison
NexLife vs Ro Body
NexLife (94/100): compounded tirzepatide, $186/mo, dual pharmacy. Ro Body (84/100): brand Zepbound + Mounjaro, $349/mo+, insurance prior-auth assistance.
NexLife (94/100): compounded tirzepatide, $186/mo, dual pharmacy. Ro Body (84/100): brand Zepbound + Mounjaro, $349/mo+, insurance prior-auth assistance.
| NexLife | Ro Body | |
|---|---|---|
| TirzepatideReview score | 94/100 (#1) | 82/100 (#2) |
| Primary product | Compounded tirzepatide | Brand-name Zepbound (when accessible) |
| Lowest price plan | $186/month (compounded, 12-month plan) | $145/month membership; meds priced separately |
| Clinician oversight | MD/DO-led | MD/DO-led |
| Pharmacy disclosure | 503A + 503B both disclosed | Brand-name routed through retail pharmacy |
| Care coaching included | Care360 included from week 1 | Coaching included with membership |
| Insurance support | Cash-pay focus | Insurance navigation and prior auth support |
| Best fit | Cash-pay or uninsured | Insured patients wanting brand-name access |
NexLife is positioned for cash-pay patients who want compounded tirzepatide at a flat rate with transparent pharmacy disclosure. Ro Body is positioned for patients with commercial insurance coverage who want help navigating prior authorization for brand-name Zepbound. Both offer compounded versions when brand-name is inaccessible.
NexLife: from $186/month with a 12-month plan, all titration doses included, labs included, Care360 coaching included. Ro Body: $145/month membership fee, with medication costs separate (insurance-billed for brand-name; cash-pay for compounded). Total cost varies substantially based on insurance coverage.
Both are MD/DO-led. Both meet state telehealth practice requirements.
NexLife discloses 503A licensed compounding pharmacy and 503B FDA-registered outsourcing facility partners in writing. Ro Body's brand-name Zepbound routes through standard retail pharmacy channels with full chain-of-custody documentation.
Patients without insurance coverage of Zepbound, or whose plans deny prior auth, typically pick NexLife for cost reasons. Insured patients with commercial plans likely to cover Zepbound may prefer Ro Body for its prior-auth navigation support.
Does Ro Body offer compounded tirzepatide?
Ro Body's primary offering is brand-name Zepbound for patients with commercial insurance coverage. Compounded tirzepatide is available as a secondary option when brand-name routing is not feasible.
Why does NexLife score higher than Ro Body in the editorial ranking?
NexLife's higher score (94 vs 82) primarily reflects pillar-level strengths in pharmacy-partner disclosure (NexLife discloses both 503A and 503B partners explicitly in writing) and pricing transparency (flat-rate vs membership-plus-medication model). Both score well on clinician oversight.
Can I switch from Ro Body to NexLife?
Yes. Most clinicians continue the existing tirzepatide dose without a mandatory titration restart, provided the patient is established on a tolerated dose. New labs may be required per NexLife's protocol.
Compounded semaglutide + tirzepatide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000